{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:16:07Z","timestamp":1778886967369,"version":"3.51.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2158"],"award-info":[{"award-number":["GRK 2158"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["270650915"],"award-info":[{"award-number":["270650915"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["813091"],"award-info":[{"award-number":["813091"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2016-02364753"],"award-info":[{"award-number":["GR-2016-02364753"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004462","name":"Consiglio Nazionale delle Ricerche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004462","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34033","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T17:04:41Z","timestamp":1720026281000},"page":"e34033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-2969","authenticated-orcid":false,"given":"Athanasios","family":"Oikonomou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titus","family":"Watrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Scharov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela Maria","family":"Savino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Schliehe-Diecks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Bardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanil","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-4528","authenticated-orcid":false,"given":"Giovanni","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Palmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34033_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"Gillies","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34033_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat. Biotechnol."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e34033_bib4","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B","article-title":"Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer","volume":"35","author":"DeVita","year":"1975","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34033_bib6","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.21873\/anticanres.13472","article-title":"To combine or not combine: drug interactions and tools for their analysis. Reflections from the EORTC-PAMM Course on preclinical and early-phase clinical pharmacology","volume":"39","author":"El Hassouni","year":"2019","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34033_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34033_bib8","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","article-title":"Harnessing connectivity in a large-scale small-molecule sensitivity dataset","volume":"5","author":"Seashore-Ludlow","year":"2015","journal-title":"Cancer Discov."},{"issue":"Database issue","key":"10.1016\/j.heliyon.2024.e34033_bib9","first-page":"D955","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34033_bib10","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-15-0843","article-title":"An unbiased oncology compound screen to identify novel combination strategies","volume":"15","author":"O'Neil","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34033_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.drudis.2015.09.003","article-title":"Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives","volume":"21","author":"Bulusu","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.heliyon.2024.e34033_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-020-0122-1","article-title":"Machine learning approaches to drug response prediction: challenges and recent progress","volume":"4","author":"Adam","year":"2020","journal-title":"npj Precis. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34033_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34033_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10091926","article-title":"Advances in the diagnosis and treatment of pediatric acute lymphoblastic leukemia","volume":"10","author":"Inaba","year":"2021","journal-title":"J. Clin. Med."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e34033_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1615\/CritRevOncog.v16.i1-2.30","article-title":"Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia","volume":"16","author":"Tasian","year":"2011","journal-title":"Crit. Rev. Oncog."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34033_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220026","article-title":"CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition","volume":"14","author":"Meyer","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34033_bib18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34033_bib19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34033_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34033_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062193","article-title":"The current genomic and molecular landscape of philadelphia-like acute lymphoblastic leukemia","volume":"21","author":"Shiraz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34033_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34033_bib23","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/leu.2012.101","article-title":"Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia","volume":"26","author":"Palmi","year":"2012","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.heliyon.2024.e34033_bib24","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34033_bib25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34033_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000892","article-title":"Definition and prognostic value of ph-like and IKZF1plus status in children with Down syndrome and B-cell precursor acute lymphoblastic leukemia","volume":"7","author":"Palmi","year":"2023","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34033_bib27","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/leu.2017.93","article-title":"The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL","volume":"31","author":"Savino","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34033_bib28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e34033_bib29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2018-99-110221","article-title":"A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/aall1521): dose-finding results from the Part 1 safety phase","volume":"132","author":"Tasian","year":"2018","journal-title":"Blood"},{"issue":"1\u201312","key":"10.1016\/j.heliyon.2024.e34033_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","article-title":"The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo","volume":"11","author":"Leoni","year":"2005","journal-title":"Mol Med"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34033_bib31","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.leu.2404860","article-title":"The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells","volume":"21","author":"Golay","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34033_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34033_bib33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","article-title":"Givinostat: an emerging treatment for polycythemia vera","volume":"29","author":"Chifotides","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34033_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34033_bib35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/1120009X.2016.1145375","article-title":"Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies","volume":"28","author":"Ganai","year":"2016","journal-title":"J. Chemother."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34033_bib36","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/art.30238","article-title":"Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis","volume":"63","author":"Vojinovic","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34033_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.heliyon.2024.e34033_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104224","article-title":"PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120,","volume":"83","author":"Fazio","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib39","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e34033_bib80","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.5334\/ojb.15","article-title":"Galliera Genetic Bank: A DNA and Cell Line Biobank from Patients Affected by Genetic Diseases. Open Journal of Bioresources","volume":"3","author":"Baldo","year":"2016","journal-title":"Open Journal of Bioresources"},{"key":"10.1016\/j.heliyon.2024.e34033_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1755-8794-6-24","article-title":"Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome","volume":"6","author":"Granese","year":"2013","journal-title":"BMC Med Genomics"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34033_bib41","first-page":"587","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Dev. Reprod. Biol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34033_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34033_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34033_bib44","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nmeth.2689","article-title":"DGIdb: mining the druggable genome","volume":"10","author":"Griffith","year":"2013","journal-title":"Nat. Methods"},{"issue":"43","key":"10.1016\/j.heliyon.2024.e34033_bib45","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.2008.07562.x","article-title":"Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells","volume":"145","author":"Jourdan","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e34033_bib47","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3389\/fgene.2019.00858","article-title":"pathfindR: an R package for comprehensive identification of enriched pathways in omics data through active subnetworks","volume":"10","author":"Ulgen","year":"2019","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e34033_bib48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34033_bib49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3324\/haematol.2022.280879","article-title":"BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia","volume":"108","author":"Tsuzuki","year":"2023","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.heliyon.2024.e34033_bib50","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1158\/0008-5472.CAN-16-0523","article-title":"Acute sensitivity of ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant","volume":"76","author":"Richmond","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/JCI135937","article-title":"DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3","volume":"131","author":"Bhansali","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e34033_bib52","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1172\/JCI140797","article-title":"Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo","volume":"130","author":"Lopez-Lopez","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"26","key":"10.1016\/j.heliyon.2024.e34033_bib53","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1182\/blood-2009-11-256131","article-title":"Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol","volume":"115","author":"Cario","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e34033_bib54","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1182\/blood-2012-02-413252","article-title":"Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2","volume":"120","author":"van Bodegom","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib55","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41598-019-41078-4","article-title":"Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"9","author":"Steeghs","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34033_bib56","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2015.359","article-title":"Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia","volume":"30","author":"Marke","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.heliyon.2024.e34033_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215384","article-title":"A comprehensive overview of recent advances in epigenetics in pediatric acute lymphoblastic leukemia","volume":"14","author":"Dro\u017cak","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e34033_bib58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e34033_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2020.578011","article-title":"Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials","volume":"11","author":"Hontecillas-Prieto","year":"2020","journal-title":"Front. Genet."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e34033_bib60","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e34033_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41389-018-0026-x","article-title":"Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma","volume":"7","author":"Di Martile","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1016\/j.heliyon.2024.e34033_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.856804","article-title":"Dual blockade of misfolded alpha-sarcoglycan degradation by bortezomib and givinostat combination","volume":"13","author":"Hoch","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34033_bib63","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2014.81","article-title":"BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts","volume":"28","author":"Locatelli","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34033_bib64","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-013-0096-1","article-title":"Trametinib: first global approval","volume":"73","author":"Wright","year":"2013","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e34033_bib65","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"First global approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34033_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081994","article-title":"The histone deacetylase inhibitor ITF2357 (givinostat) targets oncogenic BRAF in melanoma cells and promotes a switch from pro-survival autophagy to apoptosis","volume":"10","author":"Celesia","year":"2022","journal-title":"Biomedicines"},{"issue":"27","key":"10.1016\/j.heliyon.2024.e34033_bib67","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.3748\/wjg.v21.i27.8326","article-title":"Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation","volume":"21","author":"Wang","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"9\u201310","key":"10.1016\/j.heliyon.2024.e34033_bib68","doi-asserted-by":"crossref","first-page":"292","DOI":"10.18632\/genesandcancer.117","article-title":"Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia","volume":"7","author":"Li","year":"2016","journal-title":"Genes Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e34033_bib69","first-page":"4525","article-title":"ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study","volume":"30","author":"Galimberti","year":"2010","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1535-7163.MCT-22-0101","article-title":"Genotype-tailored ERK\/MAPK pathway and HDAC inhibition rewires the apoptotic rheostat to trigger colorectal cancer cell death","volume":"22","author":"Jenkins","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e34033_bib71","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-18-3382","article-title":"HDAC inhibition enhances the in vivo efficacy of MEK inhibitor therapy in uveal melanoma","volume":"25","author":"Fai\u00e3o-Flores","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e34033_bib72","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2017-06-792150","article-title":"Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients","volume":"130","author":"Cyrenne","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e34033_bib73","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13148-022-01306-7","article-title":"Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression","volume":"14","author":"Cao","year":"2022","journal-title":"Clin Epigenetics"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e34033_bib74","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3324\/haematol.2018.211110","article-title":"Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma","volume":"104","author":"Ramakrishnan","year":"2019","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.heliyon.2024.e34033_bib75","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.2021014241","article-title":"Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1","volume":"140","author":"Janssen","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e34033_bib76","first-page":"1034","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e34033_bib77","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e34033_bib78","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/10428194.2017.1366999","article-title":"Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies","volume":"59","author":"Grant","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e34033_bib79","first-page":"741","article-title":"Trametinib: a targeted therapy in metastatic melanoma","volume":"9","author":"Hoffner","year":"2018","journal-title":"J Adv Pract Oncol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024100643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024100643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:03:07Z","timestamp":1778886187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024100643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":80,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024100643"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34033","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34033"}}